Perspective Therapeutics (CATX) Net Cash Flow (2010 - 2026)
Perspective Therapeutics (CATX) posted Net Cash Flow of $23.3 million for Q1 2026, up 503.65% sequentially from $3.9 million in Q4 2025, and up 235.92% YoY from $6.9 million in Q1 2025.
Perspective Therapeutics (CATX) Net Cash Flow (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Net Cash Flow for 17 years, with the latest figure at $23.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 235.92% year-over-year to $23.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.6 million (up 109.77% YoY) and the FY2025 annual result came in at -$31.0 million, down 159.34% from the prior year.
- Net Cash Flow advanced to $23.3 million in Q1 2026 per CATX's latest filing, from $3.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $132.9 million in Q1 2024 and troughed at -$164.9 million in Q4 2024.
- A 5-year average of -$2.9 million and a median of -$8.1 million in 2023 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 1834.75% in 2022, then surged 1451.13% in 2024.
- Over 5 years, Net Cash Flow stood at -$34.9 million in 2022, then surged by 74.94% to -$8.7 million in 2023, then plunged by 1785.23% to -$164.9 million in 2024, then surged by 102.35% to $3.9 million in 2025, then soared by 503.65% to $23.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $23.3 million, $3.9 million, and -$2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.79 Bn | 195.19 Bn | 7.27 Bn | -1.70 Bn |
| 2 | Stryker | 125.96 Bn | 122.49 Bn | 4.50 Bn | 527.00 Mn |
| 3 | Medtronic | 118.43 Bn | 109.21 Bn | 6.41 Bn | 768.00 Mn |
| 4 | Boston Scientific | 73.13 Bn | 72.59 Bn | 3.85 Bn | -892.00 Mn |
| 5 | Edwards Lifesciences | 51.63 Bn | 47.38 Bn | 1.35 Bn | 458.40 Mn |
| 6 | Dexcom | 34.60 Bn | 32.65 Bn | 830.00 Mn | -8.30 Mn |
| 7 | GE HealthCare Technologies | 33.71 Bn | 31.60 Bn | 2.18 Bn | -183.00 Mn |
| 8 | Koninklijke Philips | 26.17 Bn | 22.85 Bn | 4.55 Bn | -926.40 Mn |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | 45.10 Mn |
| 10 | Perspective Therapeutics | 405.51 Mn | 405.51 Mn | - | -5.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.48 Mn |
| Jun 30, 2026 | -5.48 Mn |
| Mar 31, 2026 | 23.34 Mn |
| Mar 31, 2026 | 23.34 Mn |
| Dec 31, 2025 | 3.87 Mn |
| Dec 31, 2025 | 3.87 Mn |
| Sep 30, 2025 | -2.09 Mn |
| Sep 30, 2025 | -2.09 Mn |
| Jun 30, 2025 | -15.56 Mn |
| Jun 30, 2025 | -15.56 Mn |
| Mar 31, 2025 | -17.17 Mn |
| Mar 31, 2025 | -17.17 Mn |
| Dec 31, 2024 | -164.86 Mn |
| Dec 31, 2024 | -164.86 Mn |
| Sep 30, 2024 | -25.74 Mn |
| Sep 30, 2024 | -25.74 Mn |
| Jun 30, 2024 | 109.89 Mn |
| Jun 30, 2024 | 109.89 Mn |
| Mar 31, 2024 | 132.88 Mn |
| Mar 31, 2024 | 132.88 Mn |